Mirum Pharmaceuticals, Inc.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS9
PHASE 3 / 2-35
RECRUITING3
READOUTS ≤12 MONTHS4
READOUT SLIPPED >6 MO50%
Delay Index: of 6 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +23.0 months). See all sponsors →
Open Mirum Pharmaceuticals, Inc. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| VISTAS NCT04663308 |
P2 | Active, not recruiting | Primary Sclerosing Cholangitis | 182 | 2026-02-20 (+39 mo) |
| Maralixibat NCT06553768 |
P3 | Active, not recruiting | Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC) | 90 | 2026-07-29 (-1 mo) |
| Brelovitug 300 mg NCT07298330 |
P3 | Active, not recruiting | Chronic Hepatitis D Infection | 80 | 2026-08 |
| VANTAGE NCT05050136 |
P2 | Active, not recruiting | Primary Biliary Cholangitis; PBC | 333 | 2027-01 (+37 mo) |
| Brelovitug 300 mg NCT07200908 |
P3 | Recruiting | Chronic Hepatitis D Infection | 172 | 2027-06-30 |
| Brelovitug (BJT-778) NCT07454837 |
P2/3 | Recruiting | Chronic Hepatitis D | 120 | 2027-08-31 |
| Low dose of MRM-3379 NCT07209462 |
P2 | Recruiting | Fragile X Syndrome | 60 | 2027-10 |
| OASIS NCT07823127 |
P2 | Not yet recruiting | Intrahepatic Cholestasis of Pregnancy | 15 | 2029-01-12 |
| Brelovitug 300 mg NCT06907290 |
P2/3 | Active, not recruiting | Chronic Hepatitis D Infection | 150 | 2029-05 (+23 mo) |